Education
About Us
Working with TipRanks
Follow Us
Aziyo Biologics (ELUT)
NASDAQ:ELUT
ELUT Stock Chart & Stats
$0.91
$0.15(4.48%)
At close: 4:00 PM EST
$0.91
$0.15(4.48%)
Day’s Range― - ―
52-Week Range$0.85 - $5.12
Previous CloseN/A
Volume4.31K
Average Volume (3M)364.18K
Market Cap
$37.76M
Enterprise Value$120.52M
Total Cash (Recent Filing)$8.50M
Total Debt (Recent Filing)$28.24M
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Nov 07, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding38,081,936
10 Day Avg. Volume362,745
30 Day Avg. Volume364,181
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap3.19
Enterprise Value/Revenue5.09
Enterprise Value/Gross Profit11.39
Enterprise Value/Ebitda-8.61
Forecast
1Y Price Target
$5.50Price Target Upside504.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Market AcceptanceProduct uptake for EluPro is robust, with substantial same-center sales growth and over 100 active accounts, indicating strong market acceptance.
Product PositioningEluPro is positioned as a superior product with antibiotic properties and a soft biomatrix for better patient comfort and pacemaker protection, likely to capture significant market share.
Bears Say
Product PerformanceSimpliDerm was below expectations in Q4 due to partner Tiger working through its reorganization process.
Aziyo Biologics News
ELUT FAQ
What was Aziyo Biologics’s price range in the past 12 months?
Aziyo Biologics lowest stock price was $0.85 and its highest was $5.12 in the past 12 months.
What is Aziyo Biologics’s market cap?
Aziyo Biologics’s market cap is $37.76M.
When is Aziyo Biologics’s upcoming earnings report date?
Aziyo Biologics’s upcoming earnings report date is Nov 07, 2025 which is in 13 days.
How were Aziyo Biologics’s earnings last quarter?
Aziyo Biologics released its earnings results on Aug 14, 2025. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.17 by -$0.09.
Is Aziyo Biologics overvalued?
According to Wall Street analysts Aziyo Biologics’s price is currently Undervalued.
Does Aziyo Biologics pay dividends?
Aziyo Biologics does not currently pay dividends.
What is Aziyo Biologics’s EPS estimate?
Aziyo Biologics’s EPS estimate is -0.16.
How many shares outstanding does Aziyo Biologics have?
Aziyo Biologics has 38,081,936 shares outstanding.
What happened to Aziyo Biologics’s price movement after its last earnings report?
Aziyo Biologics reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.17. Following the earnings report the stock price went down -6.047%.
Which hedge fund is a major shareholder of Aziyo Biologics?
Among the largest hedge funds holding Aziyo Biologics’s share is Platinum Investment Management. It holds Aziyo Biologics’s shares valued at 0.
Aziyo Biologics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.22%
Trailing 12-Months
Company Description
Aziyo Biologics
Aziyo Biologics (ELUT) is a biotechnology company focused on developing regenerative medicine solutions, primarily through the utilization of human-derived extracellular matrix (ECM) technology. The company operates in the medical device and tissue regeneration sectors, offering innovative products for surgical and wound care applications. Aziyo's core products include grafts and implants that promote healing and tissue regeneration, addressing critical medical needs in areas such as orthopedics, cardiovascular, and general surgery.
ELUT Company Deck
ELUT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth and successful product launches, particularly with EluPro, alongside improved gross margins and progress in litigation settlements. However, challenges remain with SimpliDerm's performance and ongoing litigation issues.View all ELUT earnings summariesELUT Stock 12 Month Forecast
Average Price Target
$5.50
▲(504.40% Upside)
Technical Analysis
IGC Pharma
―
Sonnet BioTherapeutics Holdings
―
PolyPid
―
OnKure Therapeutics
―
Rani Therapeutics Holdings
―
Ownership Overview
27.12% Insiders
3.75% Mutual Funds
41.08% Other Institutional Investors
25.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---